

# Veronika Sexl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2089927/publications.pdf>

Version: 2024-02-01

197  
papers

11,269  
citations

29994

54  
h-index

35952

97  
g-index

201  
all docs

201  
docs citations

201  
times ranked

15901  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic TYK2 <sup>P760L</sup> kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. <i>Haematologica</i> , 2022, , .	1.7	1
2	The transcription factor HIF-1 $\alpha$ mediates plasticity of NKp46+ innate lymphoid cells in the gut. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	22
3	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2022, 6, e701.	1.2	4
4	CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML. <i>Cancers</i> , 2022, 14, 1554.	1.7	6
5	Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells. <i>Cancers</i> , 2022, 14, 1723.	1.7	8
6	Inducible deletion of CDK4 and CDK6 $\alpha$ deciphering CDK4/6 inhibitor effects in the hematopoietic system. <i>Haematologica</i> , 2021, 106, 2624-2632.	1.7	11
7	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	1.2	11
8	ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis. <i>Cancer Science</i> , 2021, 112, 1633-1643.	1.7	5
9	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors – A Strategy for Hematological Malignancies?. <i>Cancers</i> , 2021, 13, 2611.	1.7	15
10	Kinetics of CD4 $\alpha$ 1+ lymphocytes in brown trout after exposure to viral haemorrhagic septicaemia virus. <i>Journal of Fish Diseases</i> , 2021, 44, 1553-1562.	0.9	6
11	T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses In Vivo. <i>Frontiers in Immunology</i> , 2021, 12, 650977.	2.2	4
12	Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. <i>Cell Reports</i> , 2021, 35, 109209.	2.9	16
13	A STAT5 $\alpha$ -CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. <i>Blood</i> , 2021, 138, 2347-2359.	0.6	23
14	<i>Listeria monocytogenes</i> infection rewires host metabolism with regulatory input from type I interferons. <i>PLoS Pathogens</i> , 2021, 17, e1009697.	2.1	3
15	NK cells in hypoxic skin mediate a trade-off between wound healing and antibacterial defence. <i>Nature Communications</i> , 2021, 12, 4700.	5.8	29
16	A robust approach for the generation of functional hematopoietic progenitor cell lines to model leukemic transformation. <i>Blood Advances</i> , 2021, 5, 39-53.	2.5	5
17	Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance. <i>Cell Death and Disease</i> , 2021, 12, 991.	2.7	7
18	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	0.9	16

#	ARTICLE	IF	CITATIONS
19	3092 " CDK6 IN HEMATOPOIETIC STEM CELLS: MORE THAN A CELL CYCLE KINASE. <i>Experimental Hematology</i> , 2021, 100, S87.	0.2	0
20	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	1.7	27
21	Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 345-357.e9.	1.5	24
22	STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity. <i>Frontiers in Immunology</i> , 2020, 11, 2189.	2.2	15
23	CDK4/6 and MAPK" Crosstalk as Opportunity for Cancer Treatment. <i>Pharmaceuticals</i> , 2020, 13, 418.	1.7	28
24	The Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation. <i>IScience</i> , 2020, 23, 101602.	1.9	4
25	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. <i>Leukemia</i> , 2020, 35, 1964-1975.	3.3	35
26	The role of <sc>CDK6</sc> in cancer. <i>International Journal of Cancer</i> , 2020, 147, 2988-2995.	2.3	93
27	Selective reconstitution of IFN"3 gene function in Ncr1+ANK cells is sufficient to control systemic vaccinia virus infection. <i>PLoS Pathogens</i> , 2020, 16, e1008279.	2.1	13
28	Phospho"Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e312.	1.2	7
29	Loss of NKG2D in murine NK cells leads to increased perforin production upon long-term stimulation with IL"2. <i>European Journal of Immunology</i> , 2020, 50, 880-890.	1.6	9
30	CDK6 Inhibition: A Novel Approach in AML Management. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2528.	1.8	25
31	Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation. <i>Nature Communications</i> , 2020, 11, 1794.	5.8	44
32	Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1" Unleashes NK Cell Activity. <i>Immunity</i> , 2020, 52, 1075-1087.e8.	6.6	167
33	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400.	0.6	46
34	CDK8-Novel Therapeutic Opportunities. <i>Pharmaceuticals</i> , 2019, 12, 92.	1.7	29
35	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. <i>Nature Communications</i> , 2019, 10, 4741.	5.8	33
36	STAT5A and STAT5B"Twins with Different Personalities in Hematopoiesis and Leukemia. <i>Cancers</i> , 2019, 11, 1726.	1.7	38

#	ARTICLE	IF	CITATIONS
37	Twins with different personalities: STAT5B but not STAT5A has a key role in BCR/ABL-induced leukemia. <i>Leukemia</i> , 2019, 33, 1583-1597.	3.3	40
38	NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity. <i>Journal of Immunology</i> , 2019, 202, 1724-1734.	0.4	13
39	STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. <i>Leukemia</i> , 2019, 33, 2336-2340.	3.3	12
40	Myeloid Cells Restrict MCMV and Drive Stress-Induced Extramedullary Hematopoiesis through STAT1. <i>Cell Reports</i> , 2019, 26, 2394-2406.e5.	2.9	12
41	JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. <i>Frontiers in Immunology</i> , 2019, 10, 2590.	2.2	110
42	IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis. <i>Nature Communications</i> , 2019, 10, 5722.	5.8	68
43	CDK6 coordinates JAK2V617F mutant MPN via NF- $\kappa$ B and apoptotic networks. <i>Blood</i> , 2019, 133, 1677-1690.	0.6	29
44	T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function. <i>Mucosal Immunology</i> , 2019, 12, 51-63.	2.7	30
45	NK Cell Specific CDK8 Deletion Enhances Antitumor Responses. <i>Cancer Immunology Research</i> , 2018, 6, 458-466.	1.6	40
46	DKK2 imparts tumor immunity evasion through $\beta$ -catenin-independent suppression of cytotoxic immune-cell activation. <i>Nature Medicine</i> , 2018, 24, 262-270.	15.2	106
47	NKp46 Receptor-Mediated Interferon- $\gamma$ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. <i>Immunity</i> , 2018, 48, 107-119.e4.	6.6	143
48	Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 851-861.	2.7	19
49	The RNA helicase DDX3X is an essential mediator of innate antimicrobial immunity. <i>PLoS Pathogens</i> , 2018, 14, e1007397.	2.1	65
50	Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3987.	1.8	13
51	Cdk6: At the interface of Rb and p53. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1511206.	0.3	5
52	NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development. <i>Nature Immunology</i> , 2018, 19, 1083-1092.	7.0	42
53	An ERK-Dependent Feedback Mechanism Prevents Hematopoietic Stem Cell Exhaustion. <i>Cell Stem Cell</i> , 2018, 22, 879-892.e6.	5.2	84
54	Phenotyping and Target Expression Profiling of CD34+/CD38 <sup>low</sup> and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2018, 20, 632-642.	2.3	32

#	ARTICLE	IF	CITATIONS
55	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	0.6	132
56	CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. <i>Cancer Discovery</i> , 2018, 8, 884-897.	7.7	53
57	Loss of JAK1 Drives Innate Immune Deficiency. <i>Frontiers in Immunology</i> , 2018, 9, 3108.	2.2	43
58	O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. <i>Leukemia</i> , 2017, 31, 2132-2142.	3.3	47
59	NKG2D Promotes B1a Cell Development and Protection against Bacterial Infection. <i>Journal of Immunology</i> , 2017, 198, 1531-1542.	0.4	24
60	Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. <i>Nature Immunology</i> , 2017, 18, 293-302.	7.0	191
61	Cdk6 contributes to cytoskeletal stability in erythroid cells. <i>Haematologica</i> , 2017, 102, 995-1005.	1.7	24
62	It is a differentiation game: STAT5 in a new role. <i>Cell Death and Differentiation</i> , 2017, 24, 953-954.	5.0	2
63	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	0.6	24
64	Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. <i>Scientific Reports</i> , 2017, 7, 13090.	1.6	15
65	Expansion of <i>BCR<sup>+</sup>ABL<sup>+</sup></i> cells requires <i>PAK<sup>2</sup></i> but not <i>PAK<sup>1</sup></i> . <i>British Journal of Haematology</i> , 2017, 179, 229-241.	1.2	11
66	p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin. <i>Haematologica</i> , 2017, 102, 1299-1301.	1.7	2
67	Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. <i>Scientific Reports</i> , 2017, 7, 6460.	1.6	150
68	Loss of HIF-1 $\pm$ in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. <i>Nature Communications</i> , 2017, 8, 1597.	5.8	132
69	IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell Subpopulation Deteriorates Energy and Glucose Homeostasis. <i>Cell Metabolism</i> , 2017, 26, 171-184.e6.	7.2	104
70	MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis. <i>Oncogene</i> , 2017, 36, 2066-2073.	2.6	17
71	STAT5BN642H is a driver mutation for T cell neoplasia. <i>Journal of Clinical Investigation</i> , 2017, 128, 387-401.	3.9	57
72	Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. <i>Nature Communications</i> , 2016, 7, 12258.	5.8	76

#	ARTICLE	IF	CITATIONS
73	Response to interferons and antibacterial innate immunity in the absence of tyrosineâ€phosphorylated <sc>STAT</sc>. EMBO Reports, 2016, 17, 367-382.	2.0	50
74	Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncolmmunology, 2016, 5, e1186314.	2.1	13
75	Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood, 2016, 127, 2890-2902.	0.6	96
76	Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nature Communications, 2016, 7, 12528.	5.8	25
77	Cytokineâ€induced megakaryocytic differentiation is regulated by genomeâ€wide loss of a <sc>uSTAT</sc> transcriptional program. EMBO Journal, 2016, 35, 580-594.	3.5	66
78	Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Molecular Pharmacology, 2016, 89, 630-644.	1.0	8
79	STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discovery, 2016, 6, 414-429.	7.7	124
80	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clinical Cancer Research, 2016, 22, 2051-2061.	3.2	52
81	CDK6â€”a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene, 2016, 35, 3083-3091.	2.6	137
82	STATs in NK-Cells: The Good, the Bad, and the Ugly. Frontiers in Immunology, 2016, 7, 694.	2.2	91
83	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget, 2016, 7, 12191-12205.	0.8	6
84	CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood, 2015, 125, 90-101.	0.6	179
85	Antigen receptor-mediated depletion of FOXP3 in induced regulatory T-lymphocytes via PTPN2 and FOXO1. Nature Communications, 2015, 6, 8576.	5.8	27
86	Stat5 gene dosage in T cells modulates CD8+T-cell homeostasis and attenuates contact hypersensitivity response in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 67-79.	2.7	9
87	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. Medicine (United States), 2015, 94, e2388.	0.4	24
88	Myeloid <i>STAT3</i> promotes formation of colitis-associated colorectal cancer in mice. Oncolmmunology, 2015, 4, e998529.	2.1	24
89	MicroRNA-15/16 Antagonizes <i>Myb</i> To Control NK Cell Maturation. Journal of Immunology, 2015, 195, 2806-2817.	0.4	44
90	In vivotumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncolmmunology, 2015, 4, e1047579.	2.1	27

#	ARTICLE	IF	CITATIONS
91	Modeling BCR/ABL-Driven Malignancies in the Mouse. <i>Methods in Molecular Biology</i> , 2015, 1267, 263-282.	0.4	5
92	Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. <i>Leukemia</i> , 2014, 28, 1918-1922.	3.3	12
93	Lactotransferrin-Cre reporter mice trace neutrophils, monocytes/macrophages and distinct subtypes of dendritic cells. <i>Haematologica</i> , 2014, 99, 1006-1015.	1.7	15
94	Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. <i>Cancers</i> , 2014, 6, 193-210.	1.7	13
95	STAT1-S727 - the license to kill. <i>Oncolmmunology</i> , 2014, 3, e955441.	2.1	9
96	Differentiation of Type 1 ILCs from a Common Progenitor to All Helper-like Innate Lymphoid Cell Lineages. <i>Cell</i> , 2014, 157, 340-356.	13.5	939
97	PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. <i>Leukemia</i> , 2014, 28, 629-641.	3.3	56
98	NK cell development in bone marrow and liver: site matters. <i>Genes and Immunity</i> , 2014, 15, 584-587.	2.2	15
99	CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551.	0.2	24
100	Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis. <i>Blood</i> , 2014, 124, 2380-2390.	0.6	26
101	Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. <i>Blood</i> , 2014, 124, 2370-2379.	0.6	90
102	Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. <i>Oncotarget</i> , 2014, 5, 9564-9576.	0.8	39
103	A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. <i>Cancer Cell</i> , 2013, 24, 167-181.	7.7	244
104	ETV6/RUNX1 Induces Reactive Oxygen Species and Drives the Accumulation of DNA Damage in B Cells. <i>Neoplasia</i> , 2013, 15, 1292-IN28.	2.3	39
105	MicroRNA-155 Tunes Both the Threshold and Extent of NK Cell Activation via Targeting of Multiple Signaling Pathways. <i>Journal of Immunology</i> , 2013, 191, 5904-5913.	0.4	51
106	JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. <i>Blood</i> , 2013, 122, 2167-2175.	0.6	83
107	CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. <i>Cell Reports</i> , 2013, 4, 437-444.	2.9	104
108	Lapatinib and doxorubicin enhance the Src-dependent antitumor immune response. <i>European Journal of Immunology</i> , 2013, 43, 2718-2729.	1.6	108

#	ARTICLE	IF	CITATIONS
109	The PPAR $\alpha$ agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 1555-1565.	1.2	32
110	Declined presentation. <i>Experimental Hematology</i> , 2013, 41, S48.	0.2	2
111	Adding a new facet to STAT5 in CML: Multitasking for leukemic cells. <i>Cell Cycle</i> , 2013, 12, 1813-1814.	1.3	20
112	Macrophage and T Cell Produced IL-10 Promotes Viral Chronicity. <i>PLoS Pathogens</i> , 2013, 9, e1003735.	2.1	55
113	Targeting PI3K $\gamma$ . <i>Oncolmmunology</i> , 2013, 2, e22272.	2.1	0
114	The tumor suppressor function of STAT1 in breast cancer. <i>Jak-stat</i> , 2013, 2, e23353.	2.2	68
115	The Tyrosine Kinase Btk Regulates the Macrophage Response to <i>Listeria monocytogenes</i> Infection. <i>PLoS ONE</i> , 2013, 8, e60476.	1.1	18
116	Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation. <i>Blood</i> , 2013, 122, 17-17.	0.6	4
117	The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph+ CML. <i>Blood</i> , 2013, 122, 3979-3979.	0.6	1
118	CDK6 and p16INK4A in lymphoid malignancies. <i>Oncotarget</i> , 2013, 4, 1858-1859.	0.8	28
119	Conditional Stat1 Ablation Reveals the Importance of Interferon Signaling for Immunity to <i>Listeria monocytogenes</i> Infection. <i>PLoS Pathogens</i> , 2012, 8, e1002763.	2.1	49
120	Bcl-2. <i>Oncolmmunology</i> , 2012, 1, 749-750.	2.1	2
121	Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. <i>Oncolmmunology</i> , 2012, 1, 1027-1037.	2.1	53
122	PDGFR blockade is a rational and effective therapy for NPM-ALK $\alpha$ -driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	15.2	113
123	BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. <i>Nature Chemical Biology</i> , 2012, 8, 285-293.	3.9	158
124	Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2 $\beta$ -deoxycytidine in anaplastic large cell lymphoma. <i>Biochimie</i> , 2012, 94, 2297-2307.	1.3	51
125	STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. , 2012, , 187-204.		0
126	PI3K $\delta$ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes. <i>PLoS ONE</i> , 2012, 7, e40852.	1.1	30



#	ARTICLE	IF	CITATIONS
127	STAT5 triggers <i>BCR-ABL1</i> mutation by mediating ROS production in chronic myeloid leukaemia. <i>Oncotarget</i> , 2012, 3, 1669-1687.	0.8	64
128	Diverging fates of cells of origin in acute and chronic leukaemia. <i>EMBO Molecular Medicine</i> , 2012, 4, 283-297.	3.3	22
129	A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.. <i>Blood</i> , 2012, 120, 2685-2685.	0.6	0
130	A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. <i>Blood</i> , 2011, 117, 1565-1573.	0.6	193
131	c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard. <i>Oncotarget</i> , 2011, 2, 422-427.	0.8	17
132	Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 3043.	3.0	10
133	Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 3224.	3.0	85
134	c-JUN promotes BCR-ABL <sup>+</sup> -induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. <i>Blood</i> , 2011, 117, 4065-4075.	0.6	34
135	The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. <i>Blood</i> , 2011, 118, 4635-4645.	0.6	30
136	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 3409-3420.	0.6	168
137	The transcription factor STAT5 drives mutation and imatinib resistance in chronic myeloid leukemia via ROS production. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	1
138	Screening for serine/threonine kinases phosphorylating Stat5. <i>BMC Pharmacology</i> , 2011, 11, A33.	0.4	0
139	PI3K $\gamma$ is indispensable for CTL-mediated cytotoxicity. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	0
140	Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. <i>Hepatology</i> , 2011, 54, 1398-1409.	3.6	100
141	Variants in STAT5B Associate with Serum TC and LDL-C Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1496-E1501.	1.8	5
142	Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. <i>Journal of Clinical Investigation</i> , 2011, 121, 2000-2012.	3.9	163
143	Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias. <i>Oncotarget</i> , 2011, 2, 1043-1054.	0.8	40
144	New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas. <i>Blood</i> , 2011, 118, 1659-1659.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a,. Blood, 2011, 118, 3399-3399.	0.6	5
146	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood, 2010, 116, 1548-1558.	0.6	56
147	Stat5 is indispensable for the maintenance of <i>bcr/abl</i> -positive leukaemia. EMBO Molecular Medicine, 2010, 2, 98-110.	3.3	206
148	Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 1007-1018.	1.9	20
149	The catalytic PI3K isoforms p110 <sup>β</sup> and p110 <sup>γ</sup> contribute to B cell development and maintenance, transformation, and proliferation. Journal of Leukocyte Biology, 2010, 87, 1083-1095.	1.5	55
150	Bcr-Abl Directly Activates Stat5 Independent of Jak2. Blood, 2010, 116, 511-511.	0.6	0
151	The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Frontiers in Bioscience - Landmark, 2009, Volume, 2944.	3.0	44
152	Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. Cancer Research, 2009, 69, 203-211.	0.4	29
153	Dendritic Cells Require STAT-1 Phosphorylated at Its Transactivating Domain for the Induction of Peptide-Specific CTL. Journal of Immunology, 2009, 183, 2286-2293.	0.4	31
154	Unexpected role of STAT1 serine727 for NK cell function. BMC Pharmacology, 2009, 9, .	0.4	0
155	Second hit influences the interaction between tumor cells and the immune system in a murine model of Burkitt's lymphoma. BMC Pharmacology, 2008, 8, .	0.4	0
156	STAT1 Ser727 " key regulator for NK cell-mediated cytotoxicity and tumor surveillance. BMC Pharmacology, 2008, 8, .	0.4	0
157	Evaluation of Stat5 as a potential drug target in bcr/abl-induced leukemias. BMC Pharmacology, 2008, 8, A4.	0.4	1
158	Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells" Biochemical and Biophysical Research Communications, 2008, 366, 869-870.	1.0	10
159	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. Journal of Immunology, 2008, 180, 5466-5476.	0.4	75
160	Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. Journal of Lipid Research, 2008, 49, 2627-2640.	2.0	42
161	Signal interception-based therapies " A double-edged sword in Bcr/abl-induced malignancies?. Leukemia and Lymphoma, 2008, 49, 620-624.	0.6	5
162	Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood, 2008, 111, 2200-2210.	0.6	85

#	ARTICLE	IF	CITATIONS
163	Leukemic challenge unmasks a requirement for PI3K $\gamma$ in NK cell-mediated tumor surveillance. <i>Blood</i> , 2008, 112, 4655-4664.	0.6	48
164	The different functions of Stat5 and chromatin alteration through Stat5 proteins. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6237.	3.0	39
165	The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. <i>Blood</i> , 2007, 110, 3374-3383.	0.6	90
166	JunB is a gatekeeper for B-lymphoid leukemia. <i>Oncogene</i> , 2007, 26, 4863-4871.	2.6	22
167	Selective serotonin reuptake inhibitors: A new modality for the treatment of lymphoma/leukaemia?. <i>Biochemical Pharmacology</i> , 2007, 74, 1424-1435.	2.0	28
168	Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. <i>Blood</i> , 2006, 107, 4898-4906.	0.6	192
169	STAT1 acts as a tumor promoter for leukemia development. <i>Cancer Cell</i> , 2006, 10, 77-87.	7.7	136
170	Inhibition of Xenograft Tumor Growth and Down-Regulation of ErbB Receptors by an Antibody Directed against Lewis Y Antigen. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 1459-1466.	1.3	26
171	The Non-Receptor-Associated Tyrosine Kinase Syk is a Regulator of Metastatic Behavior in Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1293-1299.	0.3	41
172	Clusterin Regulates Drug-Resistance in Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1300-1307.	0.3	41
173	Stat5 tetramer formation is associated with leukemogenesis. <i>Cancer Cell</i> , 2005, 7, 87-99.	7.7	213
174	Antibodies Directed against Lewis-Y Antigen Inhibit Signaling of Lewis-Y Modified ErbB Receptors. <i>Cancer Research</i> , 2004, 64, 1087-1093.	0.4	70
175	TYK2 is a key regulator of the surveillance of B lymphoid tumors. <i>Journal of Clinical Investigation</i> , 2004, 114, 1650-1658.	3.9	50
176	TYK2 is a key regulator of the surveillance of B lymphoid tumors. <i>Journal of Clinical Investigation</i> , 2004, 114, 1650-1658.	3.9	32
177	Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. <i>Blood</i> , 2003, 101, 4937-4943.	0.6	33
178	JunB inhibits proliferation and transformation in B-lymphoid cells. <i>Blood</i> , 2003, 102, 4159-4165.	0.6	76
179	MAP Kinase Stimulation by cAMP Does Not Require RAP1 but SRC Family Kinases. <i>Journal of Biological Chemistry</i> , 2002, 277, 32490-32497.	1.6	69
180	The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. <i>EMBO Journal</i> , 2002, 21, 653-664.	3.5	112

#	ARTICLE	IF	CITATIONS
181	Stat5a/b contribute to interleukin 7 $\alpha$ -induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. <i>Blood</i> , 2000, 96, 2277-2283.	0.6	184
182	Stat5a/b contribute to interleukin 7 $\alpha$ -induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. <i>Blood</i> , 2000, 96, 2277-2283.	0.6	41
183	A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. <i>Oncogene</i> , 1999, 18, 573-582.	2.6	94
184	Stat5 Is Required for IL-2-Induced Cell Cycle Progression of Peripheral T Cells. <i>Immunity</i> , 1999, 10, 249-259.	6.6	530
185	Stat5 Activation Is Uniquely Associated with Cytokine Signaling in Peripheral T Cells. <i>Immunity</i> , 1999, 11, 225-230.	6.6	161
186	Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 1091-1096.	3.3	489
187	Stimulation of the Mitogen-activated Protein Kinase via the A <sub>2A</sub> -Adenosine Receptor in Primary Human Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 5792-5799.	1.6	168
188	The Cyclin-dependent Kinase Inhibitor p21 Mediates the Growth Inhibitory Effect of Phorbol Esters in Human Venous Endothelial Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 29967-29974.	1.6	47
189	Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. <i>Journal of Endocrinology</i> , 1997, 154, 231-239.	1.2	55
190	High-glucose incubation of human umbilical-vein endothelial cells does not alter expression and function either of G-protein $\beta$ -subunits or of endothelial NO synthase. <i>Biochemical Journal</i> , 1996, 315, 281-287.	1.7	30
191	Age-Related Changes in Vascular Reactivity in Genetically Diabetic Rats. <i>Pharmacology</i> , 1995, 50, 238-246.	0.9	18
192	Stimulation of human umbilical vein endothelial cell proliferation by A <sub>2A</sub> -adenosine and $\beta$ -adrenoceptors. <i>British Journal of Pharmacology</i> , 1995, 114, 1577-1586.	2.7	64
193	Treatment of a patient with malignant mesothelioma with interferon- $\gamma$ based on in vitro sensitivity tests. <i>The Clinical Investigator</i> , 1994, 72, 317-20.	0.6	4
194	Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1994, 350, 322-8.	1.4	11
195	In vivo and in vitro primed lymphocytes correlation of cytochemically detected BLT-specific lymphoid serine protease with cytotoxic activity. <i>Journal of Immunological Methods</i> , 1993, 160, 173-180.	0.6	6
196	Incidence and phenotype restriction of lymphoid BLT-serine protease granules in spontaneously diabetes prone BB rats compared with a normal rat strain. <i>Journal of Autoimmunity</i> , 1992, 5, 581-590.	3.0	1
197	Detection of BLT substrate-specific proteases in individual human peripheral blood leucocytes and bone marrow cells. <i>Journal of Immunological Methods</i> , 1991, 142, 147-155.	0.6	16